Evidence map›Paper›PMID 42005834›Full record

ArticleMolecular therapy. Oncology2026

Chimeric antigen receptor T cell targeting CD44E variant in HCC holds therapeutic potential.

Rui Liao, Cecilia Ka Wing Chan, Yuanbin Cui, Shanglin Li, Ruiying Ma, Dongdong Peng, Piaorong Mei, Mingjing Xu, Peng Li, Nathalie Wong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rui LiaoDepartment of Surgery, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
Cecilia Ka Wing ChanDepartment of Surgery, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
Yuanbin CuiChina-New Zealand Joint Laboratory on Biomedicine and Health, State Key Laboratory of Immune Response and Immunotherapy, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, GIBH-HKU Guangdong-Hong Kong Stem Cell and Regenerative Medicine Research Centre, GIBH-CUHK Joint Research Laboratory on Stem Cell and Regenerative Medicine, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Shanglin LiDepartment of Surgery, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
Ruiying MaDepartment of Surgery, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
Dongdong PengChina-New Zealand Joint Laboratory on Biomedicine and Health, State Key Laboratory of Immune Response and Immunotherapy, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, GIBH-HKU Guangdong-Hong Kong Stem Cell and Regenerative Medicine Research Centre, GIBH-CUHK Joint Research Laboratory on Stem Cell and Regenerative Medicine, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Piaorong MeiDepartment of Surgery, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
Mingjing XuDepartment of Surgery, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
Peng LiDepartment of Surgery, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
Nathalie WongDepartment of Surgery, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies. However, its efficacy in hepatocellular carcinoma (HCC) remains limited. One major challenge is the lack of reliable tumor antigens for CAR T cell recognition. CD44E, a unique alternative splicing (AS) variant of CD44 transmembrane protein that is highly expressed in HCC tumors compared to adjacent non-tumoral liver tissues, holds promise as a potential therapeutic target. Here, we successfully developed a CD44E-specific monoclonal antibody derived from the S431 hybridoma clone. Using this antibody, we confirmed CD44E protein expression in patient-derived HCC cell lines, organoids, and primary tumor tissues. A second-generation CAR was designed by incorporating the single-chain variable fragment (scFv) of the S431 antibody. These anti-CD44E CAR T cells exhibited specific cytotoxicity against CD44-positive HCC cells in both

Indexed as

alternative splicingCAR T cell therapyCD44ECD44 variant 8–10HCCMT: Regular Issueorganoid-derived xenograftsolid tumorsT cell engineeringtumor immunotherapytumor-specific antigen

Identifiers

PMID42005834
PMCPMC13090982

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.